The Object on MSN12d
Cutting a Red Softgel | Original Sounds
January 27, 2025. More for You ...
Jupiter Neurosciences announces JOTROL manufaturing agreement with Catalent
Jupiter Neurosciences (JUNS) announced it has entered into an agreement with Catalent Pharma Solutions for the production of JOTROL softgel ...
Contract Pharma5d
Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial
Jupiter Neurosciences Inc., a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, ...
Pharmaceutical Technology7y
Catalent Plans to Expand Softgel Development and Manufacturing Capabilities and Capacity Following Accucaps Aqcuisition
Catalent has announced it has completed the acquisition of Accucaps Industries, a Canada-based developer and manufacturer of Over-the-Counter (OTC), ...
Future Market Insights8d
FMI Study Indicates Global Softgel Encapsulation Machine Market Size to Reach USD 178.8 Million by 2035, Surging at 4.4% CAGR
The global softgel encapsulation machine market is poised for substantial growth over the next decade, with a projected valuation of USD 178.8 million by 2035. This represents a c ...
greenmarketreport10d
Nextleaf loss widens despite 66% revenue growth in 2024
The company posted strong sales growth in 2024, though share-based compensation expenses weighed on its bottom line.
Pharmaceutical Technology10y
Patheon to Showcase Softgel Technologies at FCE Pharma
Patheon Inc is to launch the company’s capabilities at FCE Pharma in Sao Paulo, Brazil, 12-14 May 2014. Patheon ...
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial
JOTROL is designed to overcome the historical challenges of resveratrol by significantly enhancing bioavailability while minimizing gastrointestinal side effects. The upcoming Phase 2a trial will ...